Pharma: Despite the Offer – Biontech Closes the Former Curevac Plant
4 Articles
4 Articles
Internal documents suggest that the vaccine manufacturer negotiated for months on the sale of its mRNA laboratories in Tübingen – and then broke off. Interested parties appear to be appalled.
An investor group apparently wanted to produce mRNA vaccines for racing camels and hunting birds in Tübingen, but BioNTech rejected the takeover offer for the CureVac plant.
Düsseldorf – The biotechnology company Biontech closes its plant in Tübingen, although, according to information from the Handelsblatt, an investor consortium had offered up to 20 million euros for this. In its report published yesterday, the newspaper refers to documents on the months-long negotiations. The negotiations with the consortium...
About two weeks ago, Biontech announced the closure of three German plants, including those of the acquired Curevac plant in Tübingen. According to a report, the Mainzers had an offer for the factory.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
